The European Summit for Clinical Nanomedicine and Targeted Medicine 2015 – The Translation to Knowledge Based Medicine

Simona Dostalova^{1,2}, Marketa Vaculovicova^{1,2}, Tereza Cerna^{3,4}, Pavel Kopel^{1,2,} Sona Krizkova^{1,2}, Tomas Vaculovic⁵, Tomas Eckschlager³, Marie Stiborova⁴, Vojtech Adam^{1,2}

¹Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, Zemedelska 1, CZ-613 00 Brno, Czech Republic

²Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, CZ-616 00 Brno, Czech Republic

³Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, V Uvalu 84, CZ-150 06 Prague 5, Czech Republic

⁴Department of Biochemistry, Faculty of Science, Charles University in Prague, Hlavova 2030/8, CZ-128 40 Prague 2, Czech Republic

⁵Department of Chemistry, Faculty of Science, Masaryk University, Kotlarska 2, CZ-611 37 Brno, Czech Republic

Laboratory reports

The 8th conference and exhibition of The European Summit for Clinical Nanomedicine and Targeted Medicine was focused on the translation to knowledge based medicine. It took place on June 28 – July 1, 2015 in Basel, Switzerland in a nice venue of Congress Center right in the centre of Basel. It was attended by almost 500 people from more than 40 countries all over the world.

The meeting was very interdisciplinary, with sections regarding unsolved problems in medicine; targeted medicine; guidance for publishing; strategies for marketing; ethics or even the regulation environment for targeted medicine in different countries. The lecturers were experts in the field of nanomedicine, starting with Prof. Susumu Tonegawa, a Nobel Laureate in Physiology and Medicine for the discovery of the genetic mechanism that produces antibody diversity. Another presenting Nobel Laureate

was Prof. Gerd Binnig, who received Nobel Prize in Physics for the invention of scanning tunnelling microscope. A total of 151 lectures in 5 parallel sections were presented, as well as 66 posters.

Our group presented poster dealing with Apoferritin modified with anti-PSMA antibodies for targeted delivery to prostate cancer cells that was created with the financial support from Grant Agency of the Czech Republic (NANOCHEMO GA CR 14-18344S). This poster showed a novel design for apoferritin nanocarrier able to target to various cancer cells using specific antibodies against cancer cell membrane receptors. In vitro assays using antigen-coated plate and prostate cancer and non-malignant cell line were performed in the presented experiment.

Acknowledgement

The authors gratefully acknowledge financial support from the Grant Agency of the Czech Republic (NANOCHEMO GA CR 14-18344S).

Attachment

Figure. 1.: Conference venue in Congress Center Basel. Presented poster.



